Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• CRSwNP is expected to see a rising disease burden over the forecast period (2026-2036), driven primarily by increasing prevalence, improved diagnosis, and evolving treatment approaches

  80% confidence

• Treatment strategies are shifting beyond conventional intranasal corticosteroids, systemic steroids, and surgery toward targeted biologic therapies, enabling more personalized and sustained disease control for patients

  80% confidence

• The US had around 2 million diagnosed prevalent cases of CRSwNP in 2025

  80% confidence

• GSK has expressed continued confidence in depemokimab's potential for CRSwNP and is maintaining discussions with the FDA

  80% confidence

• Gender distribution of CRSwNP in the US shows male predominance with 55% of diagnosed prevalent cases being males

  80% confidence

• The total chronic rhinosinusitis with nasal polyps treatment market size is expected to grow positively by 2036 in the leading markets

  80% confidence

• The 7MM accounted for 4.5 million diagnosed prevalent cases of CRSwNP in 2025, which are expected to increase during the study period

  80% confidence

• The United States accounted for the largest CRSwNP treatment market size in 2025, compared to other major markets

  80% confidence

• The dynamics of the CRSwNP market are expected to change in the coming years due to the launch of emerging therapies such as Depemokimab, Verekitug (UPB-101), Lunsekimig, LY3650150, and others

  80% confidence